nivolumab,pembrolizumab
merck,bms
['gastric', 'nivolumab', 'nsclc', 'pembro', 'pancreatic', 'nivo', 'sclc']
nejm group's coverage of #asco23 continues. in this issue:
- neoadjuvant pembrolizumab for early-stage nsclc
- minimally invasive strategy for resectable pancreatic cancer
- adjuvant nivolumab + chemotherapy in advanced gastric cancer 
Save time and stay informed. Our physician-editors offer you clinical perspectives on key research and news.